Distinguished in Glutaric Acidemia Type 2

Pascal Laforet

4 Centre De Référence De Pathologie Neuromusculaire Paris Est, 
Paris, FR 
Distinguished in Glutaric Acidemia Type 2
4 Centre De Référence De Pathologie Neuromusculaire Paris Est, 
Paris, FR 
OverviewLocationsClinical Research

Overview

Pascal Laforet practices in Paris, France. Mr. Laforet is rated as a Distinguished expert by MediFind in the treatment of Glutaric Acidemia Type 2. His top areas of expertise are Pompe Disease, Glycogen Storage Disease Type 3, Rhabdomyolysis, Myotonic Dystrophy Type 2, and Thymectomy.

His clinical research consists of co-authoring 249 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Glutaric Acidemia Type 2.

Gender
Male

Locations

4 Centre De Référence De Pathologie Neuromusculaire Paris Est, Paris, France
Other Locations
APHP, Centre De Référence Maladies Neuromusculaires Paris Est, Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection: Consequences on the Severity of Myasthenic Syndrome and Reciprocal Impact of the Two Pathologies on Their Respective Treatments
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection: Consequences on the Severity of Myasthenic Syndrome and Reciprocal Impact of the Two Pathologies on Their Respective Treatments
Enrollment Status: Completed
Publish Date: October 06, 2023
An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Subjects With Fatty Acid Oxidation Disorders (FAOD)
An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Subjects With Fatty Acid Oxidation Disorders (FAOD)
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

246 Total Publications

A model to predict the 6-Minute Walk Distance in Pompe disease.
A model to predict the 6-Minute Walk Distance in Pompe disease.
Journal: Journal of neuromuscular diseases
Published: April 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Laforet's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 24 Advanced Conditions
View All 55 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile